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Abstract
Trichomonas vaginalis, the most common nonviral sexually transmitted parasite, causes283 million trichomoniasis infections
annually and is associated with pregnancy complications and increased risk of HIV-1 acquisition. The antimicrobial drug
metronidazole is used for treatment, but in a fraction of clinical cases, the parasites can become resistant to this drug. We
undertook sequencing of multiple clinical isolates and lab derived lines to identify genetic markers and mechanisms of metro-
nidazole resistance.Reducedrepresentationgenomesequencingof100T. vaginalisclinical isolates identified3,923SNPmarkers
and presence of a bipartite population structure. Linkage disequilibrium was found to decay rapidly, suggesting genome-wide
recombination and the feasibility of genetic association studies in the parasite. We identified 72 SNPs associated with metronida-
zole resistance, and a comparison of SNPs within several lab-derived resistant lines revealed an overlap with the clinically resistant
isolates. We identified SNPs in genes for which no function has yet been assigned, as well as in functionally-characterized genes
relevant to drug resistance (e.g., pyruvate:ferredoxin oxidoreductase). Transcription profiles of resistant strains showed common
changes in genes involved in drug activation (e.g., flavin reductase), accumulation (e.g., multidrug resistance pump), and detoxi-
fication (e.g., nitroreductase). Finally, we identified convergent genetic changes in lab-derived resistant lines of Tritrichomonas
foetus, a distantly related species that causes venereal disease in cattle. Shared genetic changes within and between T. vaginalis
and Tr. foetus parasites suggest conservation of the pathways through which adaptation has occurred. These findings extend our
knowledge of drug resistance in the parasite, providing a panel of markers that can be used as a diagnostic tool.
Key words: Trichomonas vaginalis, sexually transmitted infection, comparative genomics, genetic association study,
antimicrobial drug resistance.
Introduction
Trichomonads are haploid unicellular microaerophilic mem-
bers of eukaryotic phylum Parabasalia that infect a variety
of vertebrates including humans, wildlife, farm animals, and
pets (Maritz et al. 2014). Among the several important species
in this group is Trichomonas vaginalis, which causes tricho-
moniasis, the most common nonviral sexually transmitted dis-
ease in humans, with 3.7 million cases reported each year in
the US (Center for Disease Control and Prevention 2013).
T. vaginalis can cause long-term symptomatic infections of
vulvar and urethral regions of the genital tract (Petrin et al.
1998). Importantly, T. vaginalis infection is associated with
increased risk of HIV infection (McClelland et al. 2007), devel-
opment of prostate cancer (Sutcliffe et al. 2012; Twu et al.
2014), and complications during pregnancy, such as prema-
ture and low-weight births (Cotch et al. 1997). Another tricho-
monad, Tritrichomonas foetus, is an economically important
cattle parasite, and while only distantly related to T. vaginalis, it
nevertheless has an analogous site of infection and disease
etiology (Yule et al. 1989; Foote 1996; Frey and Muller 2012).
 The Author 2017. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution.
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A highly fragmented assembly of the160 Mb T. vaginalis
strain G3 genome generated by Sanger sequencing was pub-
lished in 2007 (Carlton et al. 2007). It consists of 17,000
scaffolds containing60,000 predicted protein coding genes,
many of them members of high copy number gene families,
and 40,000 transposable element (TE) genes distributed
among 59 TE families, members of which are highly similar
(average 97.5% identity) within a family. Identification of
meiosis-specific genes in the genome suggested that the para-
site might have a cryptic sexual cycle or may have recently lost
the ability to undergo genetic exchange (Carlton et al. 2007;
Malik et al. 2008). Genetic markers mined from the genome
have been used in population studies of the species (Conrad
et al. 2011; Cornelius et al. 2012), revealing significant T. vag-
inalis genetic diversity that is structured but unrelated to geo-
graphical origin (Conrad et al. 2012). Recently, a genome
assembly forTr. foetus strain K hasbeenpublished, that reveals
itsgenome, too, isalsohighly repetitive (Benchimoletal.2017).
Metronidazole (Mz) and tinidazole are the only two United
States Food and Drug Administration approved drugs effect-
ive against T. vaginalis (de Brum Vieira et al. 2017). However,
clinical failure of Mz treatment has been reported since 1959
(Watt and Jennison 1960) and ranges from 4% in the US
(Kirkcaldy et al. 2012) to 17% in Papua New Guinea (Upcroft
et al. 2009). Mz is a prodrug, which must be reduced at its
nitro group in order to form the nitroradical anions that are
toxic to the parasite. The electrons required for Mz activation
are generated by several mechanisms, including the reduction
of pyruvate by pyruvate:ferredoxin oxidoreductase (PFO)
(Yarlett et al. 1986a,b; Brown et al. 1999; Kulda 1999), an
enzyme found in membrane-bound organelles called hydro-
genosomes that produce ATP and hydrogen, as well as several
pathways hypothesized to exist in the cytosol (Leitsch, et al.
2009, 2010, 2014). Tr. foetus is here again similar to T. vag-
inalis in displaying both Mz resistance and related hydroge-
nosomal metabolic pathways (Kulda 1999 and Kulda et al
1984).
Aerobic and anaerobic pathways of Mz resistance have
been proposed. Clinical (aerobic) resistance is typically
observed only in the presence of oxygen, which decreases
Mz toxicity by re-oxidizing nitroradical anions before they
can damage the parasite, reverting Mz to an inactive form.
Clinically resistant T. vaginalis strains have impaired oxygen
scavenging activity and elevated levels of intracellular oxygen.
Oxygen stress response genes are thought to be involved in
aerobic Mz resistance, with NADH-dependent oxidase and
flavin reductase (FR) in particular being implicated as import-
ant enzymes involved in oxygen removal (Leitsch et al. 2012,
2014). In contrast, anaerobic resistance has typically been
observed only in vitro (Upcroft and Upcroft 2001a,b), with
the exception of strain B7268 where anaerobic resistance
developed in a patient (Voolmann and Boreham 1993).
Anaerobically resistant strains are marked by the absence of
certain hydrogenosome metabolic enzymes that would
normally activate Mz, including PFO and ferredoxin (Fd)
(Yarlett, et al. 1986a; Kulda et al. 1993; Land et al. 2004),
as well as cytosolic thioredoxin reductase (TrxR) (Leitsch et al.
2009). Aerobic and anaerobic resistance pathways are pro-
posed to be fundamentally different, although FR, whose pri-
mary role is to reduce molecular oxygen to hydrogen
peroxide, appears to be involved in both processes (Leitsch
et al. 2014). To date, studies of the mechanism of Mz resist-
ance have focused wholly on candidate genes known to be
involved in oxygen scavenging or hydrogenosome metabol-
ism, e.g., PFO, Fd, FR, and TrxR (Kulda 1999; Upcroft and
Upcroft 2001b; Pal et al. 2009; Leitsch et al. 2010, 2014).
However, alterations in these genes do not explain all cases of
Mz resistance, nor have other genes been identified as pos-
sible candidates. The aim of our study was to address these
issues by large-scale genetic comparison of Mz sensitive and
resistant strains.
High-throughput methods for large-scale genetic compari-
son and analysis of mutational phenotypes are particularly
difficult to implement in trichomonads. The highly repetitive
nature of the T. vaginalis and Tr. foetus genomes makes them
refractory to conventional short-read genome sequencing.
We therefore employed double digest restriction-site associ-
ated DNA sequencing (ddRAD-Seq) to genotype 102 T. vag-
inalis isolates from eight countries, the largest sampling of T.
vaginalis genomes reported to date. We identified single nu-
cleotide polymorphisms (SNPs) in the sequences in order to
explore population structure and genome-wide linkage dis-
equilibrium (LD) in the isolates, and provide a basis for a
genome-wide association study of Mz genetic indicators. In
addition, we compared laboratory-derived Mz resistant iso-
lates with their isogenic parents to identify SNPs that could
indicate Mz resistance pathways common to resistant lines.
Because there is no efficient high-throughput transfection
system for large-scale assay of mutational phenotypes in T.
vaginalis, we conducted whole transcriptome analysis of gene
regulation in resistant and sensitive isolates, as a proxy for
direct functional testing. Finally, to explore the universality
of the genetic bases of Mz resistance among trichomonads,
we analyzed genetic changes between a parental strain and
in vitro-derived Mz resistant lines of Tr. foetus.
Results
We used ddRAD-Seq to partially sequence genomes of 102 T.
vaginalis clinical isolates from eight countries (supplementary
fig. S1 in supplementary file S1, Supplementary Material on-
line). Sequence reads were filtered, aligned, and single nu-
cleotide polymorphisms (SNPs) were identified
(supplementary file S2, Supplementary Material online; see
“Materials and Methods” for filtering criteria). Our final set
of 3,923 high quality SNPs comprised 1,463 nonsynonymous
mutations, 879 silent (synonymous) mutations, 10 nonsense
mutations, and 1,571 intergenic mutations.
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Population Structure and Fast LD Decay Suggest
Recombination in T. vaginalis Genomes
Population structure and linkage disequilibrium (LD) proper-
ties play a key role in determining success of mapping geno-
types to phenotypes (Mu et al. 2005). The existence of genetic
subpopulations and the occurrence of LD decay over short
distances are strong indicators of genetic recombination and
sexual reproduction in a population (Tibayrenc and Ayala
2002; Halkett et al. 2005), with implications for correlating
genotypes to drug resistance. To characterize population
structure, we performed principal components analysis
(PCA) of SNPs from 102 T. vaginalis isolates (fig. 1). The first
two principal components accounted for the highest variation
within the sampled isolates and explained 10.1 and 6.1% of
the variation, respectively. Similar to published findings, these
two PCA axes split the global sample into two subpopulations
(Conrad et al. 2012; Bradic et al. 2014), a structure congruent
with sexual reproduction. Population structure did not corres-
pond to the geographical origin of the isolates.
In asexual populations, LD is maintained over long genomic
distances or even over the entire genome, while genetic ex-
change in sexually reproducing populations constrains LD to
shorter distances. We plotted LD decay along the 898 gen-
omic contigs containing 2,837 SNPs in one population, and
along the 872 contigs containing 2,694 SNPs in the other
population, and found decay occurring within 1 kb in both
populations (fig. 2), although the rate differed between
the two. These results, together with the presence of
population structure, provide strong evidence that genetic
exchange occurs, or occurred sometime in the recent
evolutionary past, of both T. vaginalis populations. The
difference in LD decay rates indicates potential differences
in recombination, population size, or phenotypic traits
(e.g., transmission, drug resistance, virulence) between
the two populations.
Association Study of T. vaginalis Isolates Identifies
Candidate Biomarkers of Mz Resistance
Our findings suggested (1) that population structure should
be accounted for in T. vaginalis association studies in order to
avoid spurious genotype-to-phenotype association; and that
(2) fast LD decay allows for mapping of phenotypic traits in
candidate regions. We first tested for association between T.
vaginalis population structure and resistance to metronidazole
(Mz) as measured using a standard minimum lethal concen-
tration (MLC) protocol under aerobic conditions (supplemen-
tary file S2, Supplementary Material online). Of the 95 isolates
for which MLC could be determined, 63 were classified as
“sensitive” and 32 as “resistant” (MLC 100lg/ml), of
which 23 were also “highly resistant” (MLC 400lg/ml).
Neither of the two subpopulations detected by PCA of
ddRAD SNPs was significantly associated with Mz resistance
(Pearson’s chi-squared test for MLC 100lg/ml: v2
¼ 0.2139, df¼NA, P-value¼ 0.8136; for MLC 400lg/ml:
v2 ¼ 0.2291, df¼NA, P-value¼ 0.7271; fig. 1).
FIG. 1.—Population structure in T. vaginalis global samples. Principal
components analysis of 102 T. vaginalis isolates using 3,923 genome-wide
ddRAD SNPs. The x-axis represents principal component one (PC1) and
explains 10.1% of the variation, while the y-axis represents principle com-
ponent two (PC2), and explains 6.1% of the variation; the inset represents
distribution of eigenvalues where each eigenvalue is the variance of the
corresponding PC. Colors show variation in 32 Mz resistant (red) and 63
Mz sensitive (blue) isolates as defined by MLC100lg/mL. Individual
isolate assignment to each sub-population cluster is summarized in sup-
plementary table S2, Supplementary Material online.
FIG. 2.—LD decays over distance in two populations of T. vaginalis. LD
decay calculated over 5kb intervals in 898 contigs (top panel) and 872
contigs (bottom panel) is shown for the two populations of T. vaginalis.
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We next used Discriminant Analysis of Principal
Components (DAPC) (Jombart et al. 2010) to identify SNPs
that distinguish Mz resistant from Mz sensitive isolates, and
quantified the contribution of each allele to this distinction
(fig. 3). Our analysis showed partial overlap of alleles between
sensitive and resistant groups (fig. 3A). We identified the SNPs
that contribute the most to distinguishing sensitive from re-
sistant phenotypes (fig. 3B). Among these, we identified a set
of 72 SNPs associated with moderate or high Mz resistance
(MLC 100lg/ml or400lg/ml; supplementary file S3,
Supplementary Material online). Along with multiple silent
(synonymous) and intergenic SNPs, we identified 16 nonsy-
nonymous SNPs associated with moderate resistance in 13
genes (e.g., TVAG_197160 CAMK family protein kinase,
TVAG_158720 BspA-like protein), and two nonsynonymous
SNPs in two conserved hypothetical genes (TVAG_124910,
TVAG_493120) associated with both moderate
(MLC 100lg/ml) and high (MLC 400lg/ml) resistance.
A summary of these genes and their SNPs is shown in sup-
plementary file S3, Supplementary Material online.
SNP Changes in Lab-derived Mz Resistant T. vaginalis Lines
Suggest Similar In Vivo and In Vitro Mechanisms of Drug
Resistance
While the 72 SNPs we found associated with moderate and
high resistance in disparate clinical isolates represent a poten-
tially important set of genetic markers of the resistance
phenotype, such association does not demonstrate causation.
To identify SNPs that may be more strongly inferred to be
consequences of adaptation to drug treatment, we exploited
existing pairs of T. vaginalis lines, each consisting of a highly
drug-resistant line derived in vitro from a naturally drug-
sensitive or moderately resistant parental line by increasing
drug selection pressure over time (supplementary file S1
and fig. S2, Supplementary Material online). We analyzed
SNPs observed in ddRAD-Seq data from three such pairs of
parental and derived lines: (1) Mz-sensitive B7708 and highly
resistant B7708-M; (2) Mz-sensitive F1623 and highly resistant
F1623-M (Brown et al. 1999); and (3) moderately resistant
B7268 and highly resistant B7268-M (Wright et al. 2010).
SNPs were identified by comparing the parental and derived
line to the reference genome of the Mz-sensitive lab strain
G3. For each pair, only bases that were the same in the par-
ental line and the G3 reference but different in the derived
strain were considered as SNPs (see “Materials and
Methods”). We found 39 nonsynonymous SNPs that were
common to all three derived, highly resistant lines, in 36 genes
(fig. 4, supplementary file S5, Supplementary Material online).
Changes common to two out of three derived lines included
seven nonsynonymous mutations in seven genes in B7708-M
and F1623-M; 137 nonsynonymous (including one nonsense)
SNP in 141 genes in B7708-M and B7268-M; and 170 non-
synonymous and two nonsense SNPs in 155 genes in F1623-
M and B7268-M. We also identified multiple synonymous and
intergenic SNPs in common between the pairs (data not
shown).
Of particular note are five genes (TVAG_124910,
TVAG_197160, TVAG_226650, TVAG_393400, and
TVAG_465880) containing nonsynonymous SNPs that were
(1) present in at least two lab-derived resistant strains, and (2)
associated with Mz resistance in our association study of
100 clinical isolates described above. TVAG_197160 enco-
des a predicted CAMK kinase family protein mentioned
A
B
SNP
L
o
ad
in
g
s
D
en
si
ty
Discriminant function 1 
TVAG_493120
TVAG_388580
TVAG_158720
TVAG_465880
TVAG_197160
TVAG_133160 TVAG_226650
TVAG_393400
TVAG_214070
TVAG_124910
TVAG_267320 TVAG_091200
TVAG_308310
FIG. 3.—Association mapping for Mz resistance in T. vaginalis. (A)
Discriminant analysis of principal components (DAPC) representing vari-
ation and distribution of markers between drug resistant (red) and drug
sensitive (blue) isolates. Ticks on the x-axis represent individual isolates. The
inset represents the distribution of eigenvalues, with the black histogram
showing all the principle components that were used in the DAPC analysis.
(B) Loadings plot of the SNPs used for association analysis. The distribution
of variances for SNP markers within and between resistant and sensitive
isolates is represented as a loading value for each marker. The loading
values above the threshold represent the largest between-group variance
and the smallest within-group variance and are associated with the resist-
ant phenotype. SNP markers are indicated on the x-axis, and the loadings
value for each SNP on the y-axis; a horizontal line indicates the loadings
threshold. Red dots represent 72 SNPs identified as significantly contribu-
ting to Mz resistance. Text in blue font represents two nonsynonymous
SNPs in two conserved hypothetical genes (TVAG_493120 and
TVAG_124910) common to both moderate (MLC100) and high
(MLC400 Mz) phenotypes.
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above, while the rest encode conserved hypothetical proteins,
one of which (TVAG_465880) contains multiple SNPs shared
between the derived and clinical isolates. These five genes
represent novel candidates for roles in both clinical and
in vitro-derived Mz resistance. A summary of the genes and
their SNPs described in this section is shown in supplementary
file S4, Supplementary Material online.
Gene Expression Changes Are Associated with Resistance
and SNPs in Clinical and Lab Derived Isolates
We employed whole transcriptome analysis to survey changes
in gene expression associated with Mz resistance. RNA-Seq
libraries in triplicate were sequenced from nine Mz-sensitive
isolates (reference strain G3 and GOR69, NYCA04, NYCB20,
NYCD15, NYCE32, NYCF20, NYCG31, and SD2), and three
resistant isolates (moderately resistant clinical isolate B7268,
its highly resistant in vitro derivative B7268-M, and highly re-
sistant clinical isolate NYCC37). Of the 57,796 predicted
protein-coding genes in the T. vaginalis G3 genome (exclud-
ing TE genes), a total of 28,919 (50%) showed evidence of
expression (supplementary file S6, Supplementary Material
online), a similar number as reported in a previous transcrip-
tome study of T. vaginalis strain TO16 (Gould et al. 2013). A
wide range of gene expression was seen between isolates
(PC1, 22.38% and PC2, 14.35% variation explained), with
the drug resistant pair B7268 and B7268M clustering to-
gether and separately from the other isolates (fig. 5A). It is
worth mentioning that a large proportion of gene expression
diversity was apparent due to variation in paralogous genes
(data not shown).
B7268M B7708M
 
F1623M
141
38
426 72
7
526
155
FIG. 4.—Common genetic changes in laboratory-derived T. vaginalis
lines. Venn diagram circle sizes are based on numbers of genes that have
nonsynonymous SNPs. A nonsynonymous SNP was defined as a position
where the nucleotide in the ancestral strain was the same as in the refer-
ence G3 strain, but different in the derived (more resistant) strain.
FIG. 5.—Differential gene expression in laboratory-derived and clinic-
ally resistant T. vaginalis versus sensitive lines. (A) Principal components
analysis of 12 isolates and their replicates based on normalized gene read
counts. Replicates are indicated as shapes and different isolates as colors.
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To identify genes whose expression is most strongly asso-
ciated with Mz resistance, we compared each of the three
resistant strains with the group of nine sensitive strains. Mz
resistant strains B7268 and B7268M shared the highest num-
ber of pairwise down- (1208) and up-regulated genes (568)
(supplementary file S6, Supplementary Material online), as
expected given their common ancestry. All three resistant
strains shared 28 upregulated and 162 downregulated genes
(FDR¼ 0.05; fig. 5B and C and supplementary file S6,
Supplementary Material online). Comparing these genes to
results from our two SNP studies described above, we identi-
fied conserved hypothetical gene TVAG_465880 that was
upregulated in at least two Mz-resistant lines (B7268M and
B7268) and was also among the five novel candidate genes
flagged in both of the studies. We also identified nine genes
with a nonsynonymous SNP that were either up- or down-
regulated in the experimentally derived B7268M isolate com-
pared to its B7268 parent. For example, dynein heavy chain
protein (TVAG_188120) had a nonsynonymous SNP and ex-
pression of the gene was downregulated in B7268M, strongly
suggesting its involvement in drug resistance. Another ex-
ample is a hypothetical gene (TVAG_258020) with one non-
synonymous SNP and downregulation of the gene in both
B7268M and clinical strain NYCC37. A summary of the genes
and their SNPs described in this section is shown in supple-
mentary file S4, Supplementary Material online.
Mz Resistance Is Associated with Regulation of Genes
Involved in Drug Activation, Accumulation, and
Detoxification
We first asked if Mz resistance is more likely to occur by drug
inactivation or cell repair processes by testing if the number of
downregulated genes (fig. 5B) is significantly higher than the
number of upregulated genes (fig. 5C). We established that
the number of downregulated genes was significantly higher
in all the comparisons, suggesting that Mz resistance predom-
inantly occurs through processes that restrict drug activation.
Next, we tested for association between the set of 162 down-
regulated and 28 upregulated genes identified as shared be-
tween the three Mz resistant strains and the Mz resistance
phenotype by cluster analysis (fig. 6). Not only did the gene
expression data cluster by phenotype, but the association was
significant (chi-square test, P¼ 2.76 e08).
Within our Gene Ontology (GO) enrichment analysis of the
162 downregulated genes, oxidoreductase, catalytic, and acid
phosphatase activities were identified as the most enriched
molecular processes (P-value< 0.05). These processes are
involved in electron transfer and thus likely highly relevant
to the activation of Mz (supplementary file S6 and table S6,
Supplementary Material online). For example, T. vaginalis oxy-
gen tolerance pathways are important mediators of Mz re-
duction (Yarlett et al. 1986b; Ellis et al. 1992; Rasoloson et al.
2001). We observed changes in multiple genes associated
with oxygen detoxification (supplementary file S6,
Supplementary Material online), including in the flavin reduc-
tase gene FR1 (TVAG_517010), identified as downregulated
in our three Mz resistant strains. It has been suggested that
nitrosoimidazol, the reduced form of Mz, can form covalent
bonds with cellular proteins such as cytosolic malate dehydro-
genase (MDH) and thioredoxin reductase (TrxR) (Leitsch et al.
2009). We observed reduced expression of two variants of
MDH (TVAG_354940 in all three resistant isolates,
TVAG_412220 in B7268 and B7268M) suggesting their po-
tential role in resistance. As a probable consequence of
reduced MDH expression, we also detected an increase in
lactate dehydrogenase (TVAG_381310) activity in B7268
and B7268M, which was reported previously (Leitsch et al.
2009). The superoxide dismutase (SOD) gene family is also
involved in scavenging oxygen reactive species as part of an
oxygen defense mechanism in T. vaginalis (Leitsch et al.
2009). We identified two downregulated paralogs of SOD
(TVAG_039980, TVAG_079600) in B7268 and NYCC37
while comparing resistant and sensitive strains. Several other
oxidoreductase genes that have not been previously reported
were downregulated in the resistant strains (TVAG_414030,
TVAG_044820, and TVAG_411220). Other proteins that
might contribute to removal of reactive oxygen and help in
establishing resistance are the thioredoxin genes (Trx).
Paralogs of these genes were upregulated either in B7268
and B7268M (TVAG_277410) or in all three resistant strains
(TVAG_253800). Finally, among the eleven Mz activating
nitroreductase (ntr) genes, we observed lowered expression
of ntr6 (TVAG_354010) in Mz resistant strains B7268 and
B7268M, and downregulation of ntr7 (TVAG_474290) (Pal
et al. 2009; Paulish-Miller et al. 2014), and two other genes
from the ntr family (TVAG_303860, TVAG_473580) in
NYCC37. The ntr gene (TVAG_499730) whose protein prod-
uct is found in the hydrogenosome (Beltran et al. 2013) and is
involved in oxygen detoxification, was downregulated in all
three resistant strains.
The hydrogenosome is a key site of accumulation and ac-
tivation of Mz. Of 359 T. vaginalis proteins predicted to be
localized to the organelle (Garg et al. 2015) our data revealed
down-regulation of several of them in the resistant strains,
such as iron-sulfur flavoproteins (TVAG_040030,
TVAG_154730, and TVAG_370510) (Smutna et al. 2014),
iron hydrogenase (TVAG_182620), alcohol dehydrogenase
(TVAG_328940), malic enzymes (TVAG_412220,
TVAG_340290, TVAG_238830, and TVAG_416100), and
FIG. 5. Continued
(B) Venn diagram of number of genes in three Mz-resistant strains whose
expression is upregulated in comparison with nine Mz-sensitive strains. (C)
Venn diagram of number of genes in the same strains whose expression is
downregulated in comparison with nine Mz-sensitive strains. Changes in
genes where difference in gene expression is significant to P<0.001 are
shown. All the circles are sized based on marker numbers.
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rubrerythrin (TVAG_064490; supplementary file S6,
Supplementary Material online). In addition, of the three
hydrogenosome-localized nitroimidazole reductase (Nim)
paralogs that code for a protein associated with Mz detoxifi-
cation in the reference strain G3, (TVAG_356810) was upre-
gulated in resistant strains B7268 and B7268M, confirming
previous functional studies that showed overexpression of this
gene in Eschericia coli inactivates Mz (Pal et al. 2009).
However, Nim1 (TVAG_005890) was downregulated in all
three resistant strains, making its role less unclear.
Of the 28 upregulated genes found in all three resistant
strains compared to the sensitive strains, 14 were enriched for
antiporter and drug transmembrane transporter GO func-
tional processes (P< 0.05; supplementary files S4 and S6,
Supplementary Material online). Multidrug resistance pump
(MDR) (TVAG_291970, TVAG_210540) and metal ABC
transporter (TVAG_254060) genes showed overexpression
in all three resistance strains, suggesting that T. vaginalis
may also use drug efflux to develop resistance. A summary
of the genes and their expression differences described in this
section is shown in supplementary files S4 and S6,
Supplementary Material online.
Similar Genetic Changes Associated with Mz Resistance
Occur in Two Distantly Related Trichomonad Species
To investigate whether there are evolutionarily common
mechanisms of Mz resistance in trichomonads, we undertook
whole genome shotgun sequencing and SNP detection of
three strains of Tritrichomonas foetus, a trichomonad distantly
related to T. vaginalis that also causes a venereal disease in
cattle. We used Mz-sensitive and Mz-resistant lines
FIG. 6.—Heatmap and cluster analysis of the association between gene expression and Mz resistance phenotype for commonly up- and down-regulated
genes in T. vaginalis. Heatmap is constructed on normalized gene read counts. Cluster analysis and chi-square analysis were performed on genes that had
significant expression changes in each resistant strain in comparison to sensitive strains. Drug resistance strains significantly clustered together based on their
gene expression profile for 162 downregulated and 28 upregulated genes (chi-square test, P¼2.76e-08). Green color represents downregulated genes, red
color represent upregulated genes in resistant strains. Pink cluster represent three resistant strains (Resistant cluster¼9 samples), while blue cluster represents
nine sensitive strains (Sensitive cluster¼27 samples) corresponding.
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KV1_M100 (exhibiting in vitro aerobic resistance) and
KV1_1MR100 (exhibiting in vitro aerobic and anaerobic Mz
resistance) derived by Kulda and colleagues from KV1 (Kulda
et al. 1984) (supplementary file S1 and fig. S3, Supplementary
Material online). Details of the sequencing are shown in
table 1. Sequenced reads of the KV1 genome were assembled
into 194,695 contigs (N50¼ 2,054 bp) with a size range of
61–19,994 bp. A BLASTX search of the KV1 assembly against
the T. vaginalisG3 reference assembly returned 28,632 ortho-
logs of T. vaginalis genes (data not shown). We identified 183
SNPs in the orthologs, 13 of which (in 13 orthologs) were
present in both Mz-resistant Tr. foetus lines (supplementary
file S7, Supplementary Material online). Of these 13 orthologs
two include genes encoding an actin-like protein
(TVAG_371880) and TPR domain-containing protein
(TVAG_371930), both upregulated in lab derived B7268M
resistant strain compared to the sensitive strains.
A few Tr. foetus hypothetical proteins with SNP changes in
either of the two Tr. foetus strains are also notable for their
orthologs in T. vaginalis exhibiting reduced transcription
(TVAG_151770, TVAG_451120, and TVAG_400730).
Moreover, two of 13 orthologs in the two species (1)
CAMK family protein kinase (TVAG_139460), and (2) GP63-
like adhesion molecule (TVAG_295740), had SNP mutations
and were also downregulated in T. vaginalis (supplementary
files S4 and 7, Supplementary Material online). It is also worth
noticing that we identified SNP changes in other orthologs
that might be important for Mz resistance including tvntr3
(TVAG_35682) and pyruvate:ferredoxin oxidoreductase genes
(TVAG_198110, TVAG_242960) that did not show changes
in our T. vaginalis transcriptome dataset (supplementary file
S4, Supplementary Material online).
Discussion
This study of genetic variation and gene expression related to
drug resistance in multiple T. vaginalis isolates is the most
comprehensive in this species to date. We successfully used
ddRAD-Seq as a method to genotype unique regions of the
highly repetitive T. vaginalis genome, demonstrating that it
can be applied to protists whose genomes are refractory to
cost-effective whole genome sequencing. Our dataset of
3,923 ddRAD-Seq SNP markers also represents a high confi-
dence set of genetic variants, and greatly expands upon the
limited number of genetic markers available for this parasite.
Using these markers, we explored the genetic diversity of T.
vaginalis and present a picture of the parasite’s population
structure and linkage disequilibrium (LD) at higher resolution
than previous studies (Conrad et al. 2012; Bradic et al. 2014).
Our study also offers a panel of biomarkers that can be used
to advance personalized treatment and prevention of
trichomoniasis.
Genetic variation and exchange through recombination is
important to consider in parasites as it influences the spread
of drug resistance and virulence genes among them. Our
study confirms the existence of two genetically distinct T.
vaginalis populations (Conrad et al. 2012; Cornelius et al.
2012; Bradic et al. 2014; Paulish-Miller et al. 2014), congru-
ent with sexually reproducing organisms (Tibayrenc and Ayala
2002). Genome-wide LD, reported from analysis of a small
number of genes in previous studies (Conrad et al. 2012;
Cornelius et al. 2012), was found to decay rapidly within 1–
5 kb in both populations, providing evidence for recent gen-
etic exchange. Differences in LD decay between the two pop-
ulations suggest that different degrees of inbreeding and
rates of transmission might be responsible for maintenance
of the two-type population structure. Based on previous work
(Conrad et al. 2012; Paulish-Miller et al. 2014), we also
expected to observe a difference in average drug susceptibility
between the two T. vaginalis populations. Higher mean values
of Mz resistance were found in one population compared to
the other (98.5 mg/ml vs. 126.2 mg/ml), although the differ-
ence was not statistically significant.
A primary goal of generating the SNP markers in this study
was to undertake a genome-wide association analysis to iden-
tify novel genetic indicators of Mz resistance. From analysis of
100 global T. vaginalis Mz resistant and sensitive strains, we
identified 72 SNPs associated with moderate or high Mz re-
sistance - a panel of biomarkers that can be used to advance
personalized treatment and prevention of trichomoniasis.
Table 1
Characteristics of Whole Genome Shotgun Sequencing Datasets of Three Tr. foetus Strains, KV1, KV1_M100, and KV1_1MR100.
Tr. foetus KV1 Tr. foetus KV1_M100 Tr. foetus KV1_1MR100
Library insert size 350bp 350bp 350bp
Read length 100 nc 100 nc 100 nc
Total no. reads 67,088,722 75,792,262 70,337,248
Coverage 44.27 46.23 49.48
Avg. GC% 30 30 30
Assembly Velvet Not done Not done
No. contigs 194,695 – –
Contig N50 2,054bp – –
No. orthologs with T. vaginalis 28,362 – –
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Currently only a single “reflex test” that identifies a mutation
in the T. vaginalis ntr6 gene by real-time PCR (http://www.
prnewswire.com/news-releases/medical-diagnostic-laborato
ries-llc-announces-a-complimentary-reflex-test-to-determine-
metronidazole-resistance-in-trichomonas-vaginalis-
145736975.html) is available for clinical testing of resistance.
Of our 72 biomarkers, several (e.g., those found in
TVAG_465880 [conserved hypothetical] and TVAG_308310
[bromodomain containing protein]) were also recurrently
identified in other analyses, such as a comparison of three
laboratory-derived Mz resistant lines with their isogenic par-
ental strains. While we were unable to undertake a direct
functional analysis of these new putative resistance mutations
and genes because of the limitations of T. vaginalis transfec-
tion, whole transcriptome analysis of three resistant and nine
sensitive isolates showed several of the mutations occurred in
genes that also showed changes in expression. We also
noticed that diversity in gene expression between isolates is
primarily due to variation in expression of paralogous genes,
as has been noted in previous studies (Pal et al. 2009;
Horvathova et al. 2012). For this reason, we suggest that
multiple isolates should be used as a control panel in expres-
sion studies of T. vaginalis.
Drug resistance in eukaryotic microbes is a complex process
and usually involves either drug activation/inactivation, or ac-
tive drug efflux/reduced drug uptake (Penuliar et al. 2015). A
major finding of this study was the many changes found in
genes coding for proteins involved in drug reduction, efflux,
and inactivation (fig. 7). First, we confirmed that down-
regulation of proteins involved in Mz activation such as nitro-
reductase (ntr) and flavin reductase 1 (FR1) are a primary
response of T. vaginalis against Mz. We observed that previ-
ously identified mutations in the ntr6 gene (Paulish-Miller
et al. 2014) are associated with down-regulation in the resist-
ant lab pair B7268 and B7268M, and that down-regulation of
other ntr genes also appears to play an important role (sup-
plementary file S4, Supplementary Material online). Our ob-
servation of FR1 reduced expression in resistant isolates is in
agreement with Leitsch et al., who first showed reduced ac-
tivity of this gene in six resistant T. vaginalis strains, and im-
portantly, restoration of Mz sensitivity upon transfection
of resistant B7268 with a plasmid bearing a functional FR1
gene (Leitsch et al. 2014). In addition, iron metabolism in
T. vaginalis is highly dependent on FR1, and thus resistant
parasites must “optimize” their iron-dependent pathways
in the absence of this protein (Leitsch et al. 2009). It is
possible that the reduced expression of many cytosolic
and hydrogenosomal metabolic pathways that we
observed, as well as reduced expression of iron-SOD and
iron-sulfur flavoproteins and genes coding for protei-
nases, was as a consequence of that optimization. The
effect that iron-induced changes have on the transcrip-
tome and proteome of T. vaginalis hydrogenosomes and
proteolytic activity has also been described by others
(Horvathova et al. 2012 ; Beltran et al. 2013; Arroyo
et al. 2015). As such, these changes in iron-dependent
Inactivation 
Efflux 
Reduction I 
Reduction II 
FIG. 7.—Summary and proposed model of Mz resistance as three major processes: (1) Drug reduction, (2) Drug Efflux, and (3) Drug inactivation. Red
color represents upregulated genes, green color represents downregulated genes.
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processes represent consequences rather than causes of
Mz resistance, and thus may play an important role in
parasite fitness.
T. vaginalis contains a large 911 BspA gene family, mem-
bers of which have been localized to the cell surface and may
be involved in pathogenicity (Noel et al. 2010). Interestingly,
we detected 14 BspA-like genes as down-regulated in our
three resistant strains compared to the sensitive strains (sup-
plementary file S6,Supplementary Material online). This is in
contrast to a recent finding by Ansell and colleagues (Ansell
et al. 2017) who showed up-regulation of 10% of VSP
(variant surface protein) genes in drug resistantGiardia strains.
Because of the possible modulation of various pathways by
iron in T. vaginalis, we consider any association between
BspA-like protein regulation and drug resistance to be most
likely an epiphenomenon.
We also confirmed a possible role for certain NimA genes
in Mz detoxification. Transfection of the nim1 gene in E. coli
made the bacterium 20 more resistant to Mz through de-
toxification of the drug to nontoxic amine (Pal, et al. 2009).
While the nim2 paralog in our studies was upregulated in our
two anaerobically resistant lab strains suggesting its import-
ance in anerobic resistance to Mz, nim1 was downregulated
in all three resistant strains indicating that its function must be
furthered studied. Finally, our study identified 14 possible
membrane transporter genes that were upregulated in resist-
ant strains, indicating that efflux pumps may play a significant
role in the phenotype. Previous work surveyed a single-
domain P-glycoprotein-like gene (Pgp) (Johnson et al. 1994),
however there was no strong evidence that this protein might
be involved in Mz resistance.
While our study is the first to provide a genome-wide scan
of genetic variation and transcriptomes in tens of T. vaginalis
strains in an attempt to identify novel genes involved in the
Mz resistance phenotype, it has limitations. For example, the
PFO-ferredoxin pathway in hydrogenosomes and TrxR path-
way in the cytosol have been described as potent activators of
Mz and linked to anaerobic resistance (Cerkasovova et al.
1984; Leitsch et al. 2009; Rasoloson et al. 2001, 2002).
However, our TrxR gene expression results are the opposite
to the expression pattern shown in other studies (Leitsch et al.
2009), possibly due to experiments being performed in differ-
ent strains, or under anaerobic conditions, or through the
analysis of gene expression at the RNA level rather than at
the protein level. In addition, our use of the “reduced repre-
sentation” sequencing method means that partial SNP cover-
age of the highly repetitive,160 Mb genome was obtained,
because re-sequencing such a repetitive genome using short
read technology would have been too challenging to analyze.
An important question arising from this work is what our
analyses reveal about the evolution of Mz resistance in T.
vaginalis or other trichomonads. We observed mutations in
genes shared between several genetically distinct laboratory-
derived T. vaginalis lines and>100 T. vaginalis clinical isolates,
as well as with the distantly related Tr. foetus that causes
venereal disease in cattle, suggesting strong natural selection
on the same sets of genes and the presence of shared path-
ways of resistance. We propose that one of the first means for
developing Mz resistance in trichomonads is the development
of tolerance to high oxygen levels, which provides a protective
mechanism against the drug (e.g., FR1, ntr).
T. vaginalis already harbors mechanisms to cope with a
highly fluctuating oxygen environment (Rasoloson et al.
2001), which may make it “pre-adapted” to Mz treatment.
This hypothesis is further supported by the extremely rapid
development of aerobic resistance under lab conditions (<50
in vitro passages), and the emergence of clinical Mz resistance
within only 2 years of introduction of the drug (Robinson
1962). Other genes may play an important role in developing
subsequently higher levels of resistance. For example, several
genes in highly resistant isolates show the same mutation
recurrently appearing accompanied by transcriptional change;
e.g., dynein heavy chain family protein (TVAG_188120), and
numerous other hypothetical proteins whose function has yet
to be determined (supplementary file S4, Supplementary
Material online). Many genes identified in our study have
also been associated with Mz resistance in other microaero-
philic parasites such as Giardia and Entamoeba (Pal et al.
2009; Penuliar et al. 2015). For example, a recent transcrip-
tomic profile of resistance in Giardia suggests also modifica-
tion of nitroreductase and oxidoreductase gene families
(Ansell et al. 2017). However, in these other species, it has
been proposed that laboratory-evolved resistant strains of
those parasites accumulate multiple changes not only bene-
ficial for resistance but also those related to decreased fitness.
As a consequence, clinical resistance in those parasites has
been purported to be rare. It is tempting to speculate in the
case of T. vaginalis that due to its “Swiss army knife” of a
genome, which shows highly duplicated gene families that
may bestow the parasite with extraordinary versatility (Barratt
et al. 2016), it is able to establish drug resistant infections
because of being able to easily compensate for fitness costs.
While the details of these mechanisms and their fitness costs
should be further explored, we provide here a first insight into
adaptation of the unicellular eukaryote T. vaginalis.
Materials and Methods
Parasite Strains, Culturing and DNA Extraction
We used a set of 102 T. vaginalis isolates originating from
eight countries: Australia (13), Italy (2), Mexico (8), Papua New
Guinea (18), South Africa (9), Mozambique (1), United States
(50), and the United Kingdom (1) (supplementary file
S2,Supplementary Material online). Most of the strains were
isolated from women undergoing routine examination in sex-
ual health clinics and then adapted to growth in culture.
Additional isolates included the reference lab strain G3, and
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three in vitro-derived Mz resistant lines and their isogenic
parents, which were made Mz resistant using the method
of Kulda et al. [21] (see Fig. S2 in Supplementary file S1,
Supplementary Material online): Mz-sensitive parental strains
F1623 and B7708 and their Mz-resistant derivatives F1623-M
and B7708-M (MLC 400lg/ml, anaerobic) (Brown et al.
1999), and moderately resistant parental strain B7268
(MLC 200lg/ml) (Voolmann and Boreham 1993) and its
derivative B7268-M (MLC 400lg/ml, aerobic and anaer-
obic) (Wright et al. 2010). All three derived lines are stably
resistant in the absence of drug pressure. We also obtained
three Tritrichomonas foetus lines derived using a similar selec-
tion method [47]: Tr. foetus KV1 is the Mz-sensitive parental
strain to two resistant lines: KV1_M100 (exhibits both in vivo
and in vitro aerobic resistance) and KV1_1MR100 (exhibits
in vitro anaerobic resistance only), respectively (see supple-
mentary fig. S3 in supplementary file S1, Supplementary
Material online). T. vaginalis and Tr. foetus isolates were cul-
tured in modified Diamond’s media as described (Conrad
et al. 2011), pelleted by centrifugation, and parasite DNA
extracted using a standard phenol–chloroform procedure
(Conrad et al. 2012).
Metronidazole Susceptibility Phenotyping
T. vaginalis susceptibility to Mz was determined using a stand-
ard minimum lethal concentration (MLC) protocol under aer-
obic conditions (Rojas et al. 2004). Each isolate was grown in
culture media in 96 well plates in the presence of serial dilu-
tions of Mz ranging from 0.2 to 400lg/ml for 48 h. The low-
est concentration at which no motile parasites were observed
by microscopy was recorded as the MLC. Each assay was
repeated two times. Control strains [CDC 252, resistant to
>400lg/ml Mz, and Mz sensitive CDC 520 (Crowell et al.
2003)] were obtained from the Centers for Disease Control
and Prevention (CDC) and used in each assay. Low-level re-
sistance was defined as aerobic MLC 50–100 mg/ml,
moderate-level resistance as 100–400 mg/ml, and high-level
resistance as 400 mg/ml or greater, as per previous studies
(Lossick et al. 1986; Kirkcaldy et al. 2012).
In Silico Restriction Enzyme Optimization for ddRAD
Sequencing
We used ddRAD-Seq to sample unique regions of the highly
repetitive T. vaginalis genome. We first evaluated in silico
digests of the reference assembly of strain G3 using several
common choices of restriction enzymes implemented in
GMBX_digest_v1.0.pl script (https://github.com/Genomics
CoreLeuven/GBSX) and the SimRAD package in R (Center
for Disease Control and Prevention 2013), starting with diges-
tion with six-base cutting site enzymes (EcoRI, PstI, SdaI, SgrAI,
and SbfI) to determine the best enzyme for cutting within
unique regions of the genome [defined as regions free of
highly repetitive TEs or genes in multicopy families, based
on the current genome annotation (www.Trichdb.org)].
EcoRI was found to cut most frequently in the unique regions
of the genome (fig. S4A in supplementary file S1,
Supplementary Material online). Subsequent testing of
EcoRI in combination with other restriction enzymes, both
experimentally (data not shown) and in silico, revealed that
a double digest of EcoRI and NlaIII produced the optimal 650–
850 bp fragment size distribution for Illumina library prepar-
ation and sequencing (fig. S4B and C in supplementary file S1,
Supplementary Material online).
ddRAD Library Preparation and Illumina Sequencing
ddRAD sequencing libraries were prepared using EcoRI and
NlaIII digested DNA followed by the protocol described in
(Peterson et al. 2012). Sequencing adapters containing a com-
binatorial in-line barcode and standard Illumina multiplexing
read index were used to individually barcode samples such
that the identity of each isolate was kept intact. Libraries were
sequenced on an Illumina HiSeq 2000 following standard
methods for cluster generation and sequencing, and paired
end (PE) reads of 100 bp were generated. Samples were de-
multiplexed and individual FASTQ files obtained using Google
Documents spreadsheets and database tools in Python
(Peterson et al. 2012).
SNP Discovery and Filtering
To estimate the SNP false discovery rate and optimize SNP
filtering, the Perl script IRMS.pl (Farrer et al. 2013) was used
to introduce 99 random SNPs into the reference G3 genome
in silico. SNPs were then detected by aligning ddRAD
sequencing G3 data to the G3 reference with introduced
SNPs using BWA version 5.09 to align reads (Li and Durbin
2009) and GATK to call variants (DePristo et al. 2011).
Multiple filtering steps included removing SNPs based on
quality (QUAL> 30), approximate read depth (DP< 5), min-
imal genotype quality (GQ< 25), quality by depth (QD< 5)
and minor allele frequency (MAF)< 0.05. We recovered
82% of introduced SNPs upon alignment with the ddRAD
re-sequenced G3 data, thus the same criteria were applied
to our actual ddRAD dataset (fig. S5 in supplementary file S1,
Supplementary Material online).
Illumina PE reads generated for 102 isolates were aligned
to the G3 reference genome in the TrichDB database
(Aurrecoechea et al. 2009) using BWA. BAM alignment files
of all sequenced isolates were merged and locally realigned to
the reference assembly using GATK RealignerTargetCreator in
order to minimize the number of mismatching bases across all
the reads (DePristo et al. 2011). Genotypes were called from
merged BAM files using GATK. In addition to the above-
mentioned filtering criteria, SNPs detected from multiple sam-
ples were further filtered by removing those with>40% miss-
ingness, and those found within TEs. These filtering steps
produced a final set of 3,923 high quality filtered SNPs from
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the 191,671 total SNPs identified from 102 T. vaginalis libra-
ries. Direct SNP comparisons between parental and drug re-
sistant derived pairs were made for each SNPs such that those
SNPs found in ancestral pair must match with reference G3
strain (sensitive), and must differ from derived stains with at
least three reads for each SNP.
Sanger Sequencing for SNP Validation
Using the reference G3 assembly in the TrichDB database
(Aurrecoechea, et al. 2009), primers were designed to 150–
300 bp regions flanking six of the 72 SNPs associated with
MLC 100lg/ml and used to amplify DNA from 20 to 24 T.
vaginalis isolates (supplementary table S1 in supplementary
file S1, Supplementary Material online). PCRs were performed
in 25 ml reactions containing 20 ng genomic DNA, 0.2 mM
of each primer, 200 mM of each dNTP, 1.5 mM MgCl2, 1 U of
Taq DNA polymerase (Sigma) and 1 PCR buffer. Standard
PCR amplification programs were used with an initial denatur-
ation for 5 min and 30 cycles, and PCR products visualized on
1.5% agarose gels. Amplicons were cleaned with QIAquick
PCR purification kit (Qiagen) and sequenced using standard
Sanger sequencing chemistry. The identity of 73% (range
63% to 88%) of the SNPs identified through ddRAD
sequencing were confirmed by Sanger sequencing.
Population Structure
Population structure was assessed from the 3,923 high-
quality SNPs representing 100 isolates using Discriminant
Analysis of Principal Component (DAPC) implemented in
the R adegenet package, using “average” in the snpzip func-
tion (Jombart 2008; Jombart et al. 2010). snpzip uses DAPC to
calculate the contribution (loadings) of each SNP to each
population group or phenotype. Correction of population
structure was performed by regressing along the first PCA
axis. DAPC with the snpzip function and centroid clustering
was also used to identify SNPs that distinguish Mz-resistant
and Mz-sensitive isolates. SNP effects from the final data set
were predicted using SnpEff (Cingolani et al. 2012), and func-
tional categories were determined using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and
Goto 2000; Kanehisa et al. 2014) metabolic enrichment tools
in TrichDB (Aurrecoechea et al. 2009).
Linkage Disequilibrium
After filtering out rare variants (MAF< 0.05), which could
give spurious LD, we recovered 3,894 SNPs from the 3,923
SNPs used to determine population structure. Filtering this set
within each population gave 2,837 SNPs covering 898 gen-
omic contigs in one population, and 2,694 SNPs covering 872
contigs in the other. Linkage disequilibrium decay from SNPs
was determined using the function r2 from the toolset PLINK
(http://pngu.mgh.harvard.edu/purcell/plink), with pairwise
r2 only considered within each contig. The decay of LD over
distance was estimated using the Hill and Weir formula
(1988), and a nonlinear model was used in order to fit the
data to the decay function.
RNA-seq of T. vaginalisMz Resistant and Sensitive Parasites
Three Mz-resistant T. vaginalis isolates (B7268, B7268-M, and
NYCC37), and nine Mz-sensitive isolates (G3, GOR69,
NYCA04, NYCB20, NYCD15, NYCE32, NYCF20, NYCG31,
and SD2) were grown overnight in 14 ml sealed tubes and
total RNA was isolated using the QiagenV
R
RNeasy Mini Kit,
including a column DNase treatment using the Qiagen
VR
RNase-Free DNase kit. Polyadenylated RNA was purified
from 5lg of total RNA using the DynabeadsVR mRNA
DIRECTTM Purification Kit. All experiments were carried out
in triplicate. First strand synthesis was carried out by mixing
the entire fraction of isolated polyAþ RNA (8ll) with 0.5ll
Random Primers (3lg/ll, Invitrogen), 10 mM DTT and 0.25ll
ANTI-RNase (15–30 U/ll, Ambion) in 1x First-Strand Synthesis
Buffer (5, Invitrogen), with incubation at 65 C for 3 min to
remove RNA secondary structures, then placed on ice. A total
of 0.5ll SuperScriptV
R
III enzyme (200 U/ll, Invitrogen) and
dNTPs to a final concentration of 0.125 mM were added to
the mixture and reverse transcription was carried out using
the following incubations: 25 C for 10 min, 42 C for 50 min,
and 70 C for 15 min. The resulting cDNA/RNA hybrid was
purified from the mix using Agencourt RNAClean XP Beads
according to manufacturer’s instructions. Second-strand syn-
thesis was carried out by mixing the purified cDNA/RNA hy-
brid with 1ll dUTP mix (10 mM, Roche), 0.5ll Ribonuclease
H (2 U/ll, Invitrogen). About 1ll DNA polymerase I (5–10 U/
ll, Invitrogen) in 1  NEB buffer 2 with 2.5 mM DTT. This
mixture was incubated at 16 C for 2.5 h. The resulting dou-
ble stranded cDNA was purified using Agencourt AMPure XP
beads according to manufactures instructions. The cDNA was
end repaired by mixing 5ll T4 DNA Polymerase (3 U/ll, NEB),
2ll Klenow DNA Polymerase (3–9 U/ll, Invitrogen), 5ll T4
Polynucleotide Kinase (10 U/ll, NEB) in 1  T4 DNA Ligase
buffer with 10 mM ATP (NEB) with 0.4 mM dNTPs. The mix-
ture was incubated at room temperature for 30 min. The end-
repaired cDNA was purified using Agencourt AMPure XP
beads according to manufactures instructions. The purified
end-repaired cDNA was then taken through A-tailing, adapter
ligation and PCR enrichment using the Illumina TruSeq
Stranded mRNA Sample Preparation Kit with different barc-
odes for each sample. The libraries were pooled and
sequenced on the Illumina HiSeq 2500 with 101 cycles,
paired-end reads, and multiplexing.
Transcriptome Analyses
Approximately 10–20 million reads were generated per RNA-
seq library. The RNA-seq data sets were aligned to the G3
reference genome sequence using BWA version 5.09 (Li and
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Durbin 2009) with 1300 bp used as a distance between the
reads, yielding an overall alignment rate of >95% for all
libraries. Counts of reads for each gene were obtained using
the program HTseq (Anders et al. 2015). The raw read counts
were normalized by rowMeans normalization function based
on counts. Quality control of the data was undertaken by
comparing the three replicates of each isolate. A statistical
test (binomialWaldTest) was used to detect up- and down-
log2 fold changes in gene expression. Differential gene ex-
pression was explored using the MAplot function in DESeq2
R package, P-values were adjusted using false discovery rate
(FDR), and only changes where padj< 0.01 were considered
significant. Expression patterns of each of the three Mz resist-
ant strains (B7268, B7268-M, and NYCC37) were compared
pair-wise against the group of nine sensitive strains (G3,
GOR69, NYCA04, NYCB20, NYCD15, NYCE32, NYCF20,
NYCG31, and SD2) using the DESeq2 R package, and
FDR¼ 0.05 and P < 0.05 (Love et al. 2014). Significantly
downregulated and upregulated expression cluster groups
identified by DESeq2 R were additionally tested for their as-
sociation with Mz susceptibility using chi-square and a cluster-
ing test in the heatmap3 R package (Zhao et al. 2014). Gene
Ontology enrichment analyses of genes was performed using
TrichDB tools and a P-value cutoff of 0.05 (Aurrecoechea et al.
2009).
Tr. foetus Whole Genome Sequencing
Whole genome sequences of three Tr. foetus samples (1) KV1
(Mz sensitive), (2) KV1_M100 (derived in vitro from KV1 and
exhibiting aerobic Mz resistance), and (3) KV1_1MR100
(derived in vitro from KV1 and exhibiting aerobic and an-
aerobic Mz resistance) as described in Kulda et al. (1984),
were generated by standard Illumina sequencing of
350 bp and 500 bp insert libraries and generation of
100 bp paired-end reads. Tr. foetus KV1 Illumina sequenc-
ing reads were assembled de novo into 194,695 contigs
(N50¼ 2,054 bp) with a size range of 61–19,994 bp using
Velvet (Zerbino 2010). Sequencing produced between
44.3 coverage and 49.5 coverage of each isolate
(Zerbino 2010). Illumina reads from KV1, KV1_M100
and KV1_1MR100 were aligned against the KV1 contigs
and SNPs were called using the same GATK pipeline as
described above for T. vaginalis SNP detection. We iden-
tified 627 high quality SNPs, of which 418 were found in
KV1_1MR100, 86 were found in KV1_M100, with 97
were shared between these two resistant lines. To anno-
tate SNPs we used BLASTX (Ye et al. 2006) (with -max_-
target_seqs 1 -culling_limit 1 -seg no) to search a local
T. vaginalis protein database and identify orthologs genes.
Only BLASTX hits>50 bp length were considered valid
and received a T. vaginalis gene attribute. Candidate
SNPs were then assigned to the appropriate T. vaginalis
orthologs.
Data Access
This project has been deposited at the Sequence Read Archive
under the accession SRP057357 and SRP057311.
Supplementary Material
Supplementary data are available at Genome Biology and
Evolution online.
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